Literature DB >> 8454912

2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C.

G Giannelli1, G Antonelli, G Fera, F Dianzani, O Schiraldi.   

Abstract

The 2',5'-oligoadenylate (2-5A) synthetase is an intracellular enzyme induced by interferon (IFN). We evaluated the serum level of this enzyme in 25 patients affected by chronic hepatitis C and treated with recombinant IFN-alpha 2b. At the end of treatment, 14 patients were classified as responders and 11 as nonresponders. Before therapy initiation no significant differences in 2-5A synthetase levels among the patients were detected, while during therapy responders showed higher mean levels of 2-5A synthetase than nonresponders. An increase in the enzyme activity was observed after 1 month of therapy, and this trend was maintained in the following 2 months. The peak of 2-5A synthetase activity was found at the end of therapy. 2-5A synthetase levels were negatively correlated with serum alanine aminotransferase (ALT). This study suggests that 2-5A synthetase may be a useful marker to monitor IFN efficacy during treatment and to predict the clinical response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8454912     DOI: 10.1089/jir.1993.13.57

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  7 in total

Review 1.  Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.

Authors:  Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C.

Authors:  G Giannelli; G Antonelli; G Fera; S Del Vecchio; E Riva; C Broccia; O Schiraldi; F Dianzani
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

3.  Alpha-Interferon for the treatment of idiopathic sudden sensorineural hearing loss.

Authors:  S Kanemaru; H Fukushima; H Nakamura; H Tamaki; Y Fukuyama; Y Tamura
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

4.  Effect of alpha interferon (IFN-alpha) on 2'-5' oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN-alpha.

Authors:  J M Pawlotsky; A G Hovanessian; F Roudot-Thoraval; N Robert; M Bouvier; G Babany; J Duval; D Dhumeaux
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 5.  Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis.

Authors:  M Haria; P Benfield
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

6.  A novel RNA molecular signature for activation of 2'-5' oligoadenylate synthetase-1.

Authors:  Virginia K Vachon; Brenda M Calderon; Graeme L Conn
Journal:  Nucleic Acids Res       Date:  2014-12-04       Impact factor: 16.971

7.  Characteristics of Human OAS1 Isoform Proteins.

Authors:  Han Di; Husni Elbahesh; Margo A Brinton
Journal:  Viruses       Date:  2020-01-29       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.